Overview
- STAT reported that Lilly quietly granted a single 79-year-old patient compassionate access earlier this year, and the company confirmed on Monday that it has built a formal expanded access program and is actively reviewing requests from doctors.
- To qualify for pre‑approval retatrutide, patients must be 18 or older, unable to join a clinical trial, have refractory obesity despite the highest approved therapy dose, and be receiving care for at least two serious obesity‑related complications.
- Retatrutide is in Phase 3 testing and has produced large average weight losses in trials, with Lilly reporting roughly 22.6% average loss at 80 weeks for the highest dose, and the company plans to file for FDA approval in the first quarter of next year.
- The earlier single‑patient case prompted public scrutiny about how patients were chosen and questions to the White House, which said the request was not for President Trump, and reporters and clinicians have sought more clarity on selection and fairness.
- Lilly and regulators say expanded access will be limited for safety and supply reasons, a stance that matters to patients who cannot join trials and to the market as Lilly scales production, including a large Houston plant the company plans to use for future obesity therapies.